Hence, ccRCC transformation and progression have been reported to affect multiple regulatory layers, beyond transcription, including the epigenome, via changes in DNA methylation of CpG islands [4], the proteome, via alterations in the mammalian target of rapamycin (mTOR) pathway [3] that in turn affects protein synthesis [5], and the metabolome, whose dysregulation is considered a hallmark of ccRCC [6–8]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.